

SUPPLEMENTARY DATA

Supplementary Table S1: Etanercept Dosing Schedule Months 0-6 (mg)

<i>Week</i>	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
<i>Group 1</i>	0	50	50	50	0	50	50	50	0	50	50	50	0	50	50	0	50	50	0	50	50	0	50	50	0	50
<i>Group 2</i>	0	50	50	50	0	50	50	0	50	50	0	50	0	50	0	50	0	50	0	50	0	0	50	0	0	50
<i>Control</i>	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50

Supplementary Table S2. Adalimumab Dosing Schedule Months 0-6 (mg)

<i>Week</i>	2	4	6	8	10	12	14	16	18	20	22	24	26
<i>Group 1</i>	0	40	40	40	0	40	40	0	40	40	0	40	40
<i>Group 2</i>	0	40	0	40	0	40	0	40	0	0	40	0	0
<i>Control</i>	40	40	40	40	40	40	40	40	40	40	40	40	40

Supplementary Table S3: Etanercept Dosing Schedule Months 7-12 (mg)

<i>Week</i>	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
<i>Group 1</i>	0	50	0	0	50	0	0	0	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<i>Group 2</i>	0	0	0	50	0	0	0	0	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<i>Control A</i>	0	50	50	50	0	50	50	50	0	50	50	50	0	50	50	0	50	50	0	50	50	0	50	50	0	50
<i>Control B</i>	0	50	50	50	0	50	50	0	50	50	0	50	0	50	0	50	0	50	0	50	0	0	50	0	0	50

Supplementary Table S4: Adalimumab Dosing Schedule Months 7-12 (mg)

<i>Week</i>	28	30	32	34	36	38	40	42	44	46	48	50	52
<i>Group 1</i>	0	0	40	0	0	0	0	0	0	0	0	0	0
<i>Group 2</i>	40	0	0	40	0	0	0	0	0	0	0	0	0
<i>Control A</i>	0	40	40	40	0	40	40	0	40	40	0	40	40
<i>Control B</i>	0	40	0	40	0	40	0	40	0	0	40	0	0

Supplementary Table S5: Individual mean (standard errors) for secondary outcome measures by treatment group

Outcome	33% Tapering (n=26)			66% Tapering (n=21)			Controls (n=50)		
	<i>Baseline</i>	<i>6 months</i>	<i>Change</i>	<i>Baseline</i>	<i>6 months</i>	<i>Change</i>	<i>Baseline</i>	<i>6 months</i>	<i>Change</i>
	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>	<i>Mean (SE)</i>
DAS28-ESR	1.75 (0.16)	1.97 (0.13)	0.22 (0.17)	1.74 (0.20)	2.28 (0.26)	0.54 (0.20)	1.96 (0.11)	2.16 (0.13)	0.21 (0.11)
DAS28-CRP	2.14 (0.09)	2.15 (0.09)	0.01 (0.13)	2.02 (0.11)	2.29 (0.22)	0.27 (0.17)	2.13 (0.08)	2.30 (0.10)	0.17 (0.08)
Tender Joint Counts	0.27 (0.13)	0.36 (0.15)	0.16 (0.19)	0.52 (0.28)	2.05 (0.81)	1.55 (0.78)	0.49 (0.13)	0.96 (0.25)	0.47 (0.22)
Swollen Joint Counts	0.35 (0.17)	0.36 (0.14)	0.01 (0.16)	0.05 (0.05)	0.65 (0.27)	0.60 (0.29)	0.42 (0.16)	0.57 (0.22)	0.14 (0.18)
ESR	14.5 (3.15)	13.16 (2.29)	-1.32 (2.83)	13.45 (3.28)	11.75 (2.30)	-1.70 (2.15)	13.71 (1.71)	13.76 (1.55)	0.04 (1.10)
CRP	5.38 (0.82)	4.56 (0.62)	-0.84 (0.97)	6.90 (1.92)	3.95 (1.05)	-2.95 (1.88)	5.67 (0.97)	6.90 (1.82)	1.22 (1.03)
Assessor Global	5.92 (1.65)	7.08 (1.63)	1.16 (1.12)	6.15 (1.48)	12.85 (3.55)	6.70 (3.11)	5.90 (1.01)	9.39 (2.10)	3.49 (2.10)
Patient Global	10.4 (2.16)	10.80 (2.14)	0.40 (1.25)	10.35 (2.74)	14.70 (3.30)	4.35 (2.86)	9.67 (1.56)	11.90 (2.15)	2.22 (2.08)
HAQ	0.80 (0.15)	0.80 (0.16)	0	0.60 (0.17)	0.69 (0.17)	0.09 (0.07)	0.81 (0.11)	0.73 (0.11)	-0.07 (0.05)
EQ5D-3L	0.82 (0.04)	0.75 (0.05)	-0.07 (0.04)	0.82 (0.03)	0.77 (0.05)	-0.04 (0.04)	0.77 (0.03)	0.77 (0.03)	-0.01 (0.03)
VAS Pain	9.7 (2.6)	17.2 (4.0)	1.1 (2.2)	12.1 (2.9)	18.6 (4.5)	2.7 (2.6)	12.6 (2.2)	14.4 (2.7)	-0.7 (2.2)
FACIT Fatigue	38.9 (1.5)	38.7 (1.8)	-0.2 (1.0)	38.1 (2.2)	39.6 (2.4)	1.5 (1.8)	40.0 (1.1)	39.3 (1.3)	-0.7 (0.8)
Larsen Score	48.1 (9.4)	49.2 (9.6)	1.1 (0.6)	49.4 (9.3)	51.1 (9.4)	1.9 (0.7)	66.9 (7.2)	68.2 (7.3)	1.3 (0.5)